Cure8 trial brief
This trial tests whether a seaweed-derived fucoidan given with standard 5-ASA therapy can change biomarkers linked to mucosal healing (fecal calprotectin, fecal short-chain fatty acids) and stool consistency in people with ulcerative colitis.
Positive findings could support a new complementary prebiotic strategy for restoring gut health in UC.
Adults with ulcerative colitis, clinicians who treat UC, researchers studying microbiome-targeted or adjunctive therapies, and patients interested in complementary prebiotic strategies alongside standard medications.
This is an interventional, placebo-controlled study comparing oral low-molecular-weight fucoidan plus 5-aminosalicylic acid (5-ASA) versus placebo plus 5-ASA over 12 weeks.
The trial’s primary outcome is change in intestinal inflammation measured by fecal calprotectin; secondary mechanistic outcomes include fecal short-chain fatty acids and stool consistency. The study is registered as Phase 1/2 and enrolls adults 18–64 with active mild–moderate UC.
What this does not tell you: Registration and a Phase 1/2 design do not mean the supplement is proven effective or safe for UC; the record describes planned measurements and rationale based on preclinical data. Results are not reported in this registry entry, so clinical benefit and safety in UC remain unestablished.
Practical note: If you’re considering supplements or complementary therapies while on 5-ASA or other IBD treatments, discuss this with your care team before changing your regimen.
This is a registered Phase 1/2 interventional trial (enrolling by invitation) that outlines planned endpoints and rationale but does not present trial results. Much of the biological rationale is drawn from preclinical and in vitro studies; human efficacy and safety in UC are unproven until trial results are available.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Early-phase trials test whether new treatments are safe and show biological activity. This study measures fecal calprotectin, a biomarker of intestinal inflammation, so it could provide early signals about whether ND-12...
The article explains how gut bacteria may contribute to IBD and summarizes common tests and treatments people are likely to encounter. It highlights emerging microbial therapies (probiotics and FMT) that some patients...
Early changes in stool tests (qFIT and fecal calprotectin) might help predict which biologic‑naive ulcerative colitis patients will relapse or need escalation to biologic/JAK therapy. If validated, such markers could...
